Expression of concern: Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials (Expert Opinion on Biological Therapy, (2012), 12, 8, (1113-24), 10.1517/14712598.2012.704014);Berberine on metabolic and cardiovascular risk factors: An analysis from preclinical evidences to clinical trials

Expert Opinion on Biological Therapy

Volumn 12, Issue 8, 2012, Pages 1113-1124

  Derosa, Giuseppe ^a   Maffioli, Pamela ^a   Cicero, Arrigo F G ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

berberine; glycemic control; insulin resistance; lipid profile

Indexed keywords

ANTILIPEMIC AGENT; BERBERINE; LIPID;

BRADYCARDIA; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONSTIPATION; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; NAUSEA AND VOMITING; NEOPLASM; NONHUMAN; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; REVIEW; SKIN IRRITATION; STRUCTURE ACTIVITY RELATION;

EID: 84863789913     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2018.1475325     Document Type: Erratum

References (92)

1. Whiting DR, Guariguata L, Weil C, et al. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21
2. Muller-Nordhorn J, Binting S, Roll S, et al. An update on regional variation in cardiovascular mortality within Europe. Eur. Heart J 2008;29:1316-26
3. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
4. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012;35:S11-63
5. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12
6. Senecal M, Fodor G, Gagne C, et al. Limitations of statin monotherapy for the treatment of dyslipidemia: A projection based on the Canadian lipid study-observational. Curr Med Res Opin 2009;25:47-55
7. Suksomboon N, Poolsup N, Boonkaew S, et al. Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. J Ethnopharmacol 2011;137:1328-33
8. Cicero AFG, Ertek S. Berberine: Metabolic and cardiovascular effects in preclinical and clinical trials. Nutr Diet Suppl 2009;1:1-10
9. Birdsall TC, Kelly GS. Berberine: Therapeutic potential of an alkaloid found in several medicinal plants. Altern Med Rev 1997;2: 94-103
10. Kong WJ, Zhang H, Song DQ, et al. Berberine reduces insulin resistance through protein kinase C-dependent upregulation of insulin receptor expression. Metabolism 2009;58:109-19
11. Ko BS, Choi SB, Park SK, et al. Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma. Biol Pharm Bull 2005;28:1431-7
12. Zhang W, Xu YC, Guo FJ, et al. Antidiabetic effects of cinnamaldehyde and berberine and their impacts on retinol binding protein 4 expression in rats with type 2 diabetes mellitus. Chin Med J 2008;121:2124-8
13. Yin J, Hu R, Chen M, et al. Effects of berberine on glucose metabolism in vitro. Metabolism 2002;51:1439-43
14. Lu SS, Yu YL, Zhu HJ, et al. Berberine promotes glucagons like peptide-1(7-36 amide) secretion in streptozocin-induced diabetic rats. J Endocrinol 2009;200:159-65
15. Wang ZQ, Lu FE, Leng SH, et al. Facilitating effects of berberine on rat pancreatic islets Through modulating hepatic nuclear factor 4 alpha expression and glucokinase activity. World J Gastroenterol 2008;14:6004-11
16. Leng S, Lu F, Xu L. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin 2004;25:496-502
17. Xia X, Weng J. Targeting metabolic syndrome: Candidate natural agents. J Diabetes 2010;2:243-9
18. Zhou L, Wang X, Shao L, et al. Berberine acutely inhibits insulin secretion from beta-cells through 3¢,5¢-cyclic adenosine 5¢-monophosphate signaling pathway. Endocrinology 2008;149:4510-18
19. Zhou J, Zhou S, Tang J, et al. Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats. Eur J Pharmacol 2009;606:262-8
20. Turner N, Li JY, Gosby A, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: A mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008;57:1414-18
21. Xia X, Yan J, Shen Y, et al. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS one 2011;6:e16556
22. Ma X, Egawa T, Kimura H, et al. Berberine-induced activation of 5¢-adenosine monophosphate-activated protein kinase and glucose transport in rat skeletal muscles. Metabolism 2010;59:1619-27
23. Xie X, Li W, Lan T, et al. Berberine ameliorates hyperglycemia in alloxan-induced diabetic C57BL/6 mice through activation of Akt signaling pathway. Endocr J 2011;58:761-8
24. Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 2008;22:999-1012
25. Yin J, Zhang H, Ye J. Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2008;8:99-111
26. Yi P, Lu FE, Xu LJ, et al. Berberine reverses free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes through targeting IKKbeta. World J Gastroenterol 2008;14:876-83
27. Xing LJ, Zhang L, Liu T, et al. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. Eur J Pharmacol 2011;668:467-1
28. Kim SH, Shin EJ, Kim ED, et al. Berberine activated GLUT-1-mediated glucose uptake in 3T3-L1 adipocytes. Biol Pharm Bull 2007;30:2120-5
29. Yin J, Gao Z, Liu D, et al. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab 2008;294:E148-56
30. Zhou L, Yang Y, Wang X, et al. Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism 2007;56:405-12
31. Cheng Z, Pang T, Gu M, et al. Berberine stimulated glucose uptake in L6 myotubes includes both AMPK and p 38 MAPK. Biochim Biophys Acta 2006;1760:1682-9
32. Zhou JY, Zhou SW, Zhang KB, et al. Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biol Pharm Bull 2008;31:1169-76
33. Huang C, Zhang Y, Gong Z, et al. Berberine inhibits 3T3L1 adipocyte differentiation through the PPARgamma pathway. Biochem Biophys Res Commun 2006;348:571-8
34. Wang SH, Wang WJ, Wang XF, et al. Effects of Astragalus polysaccharides and berberine on carbohydrate metabolism and cell differentiation in 3T3-L1 adipocytes. Zhongguo Zhong Xi Yi Jie He Za Zhi 2004;24:926-8
35. Han J, Lin H, Huang W. Modulating gut microbiota as an anti-diabetic mechanism of berberine. Med Sci Monit 2011;17:RA164-7
36. Xie W, Gu D, Li J, et al. Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. PLoS one 2011;6:e24520
37. Liu WH, Hei ZQ, Nie H, et al. Berberine ameliorates renal injury in streptozocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase. Chin Med J 2008;121:706-12
38. Liu W, Tang F, Deng Y, et al. Berberine reduces fibronectin and collagen accumulation in rat glomerular mesangial cells cultured under high glucose condition. Mol Cell Biochem 2009;325:99-105
39. Abidi P, Zhou Y, Jiang JD, et al. Extracellular signal regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol 2005;25:2170-6
40. Lee S, Lim HJ, Park JH, et al. Berberine induced LDLR up-regulation involves JNK pathway. Biochem Biophys Res Commun 2007;362:853-7
41. Cameron J, Ranheim T, Kulseth MA, et al. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis 2008;201:266-73
42. Li H, Park S, Lee H-S, Liu J. HNF1alpha plays a critical role in pcsk9 gene transcription and regulation by a natural hypocholesterolemic compound berberine. J Biol Chem 2009;284:28885-95
43. Li H, Chen W, Zhou Y, et al. Identification of mRNA binding proteins that regulate the stability of LDL receptor mRNA through AU-rich elements. J Lipid Res 2009;50:820-31
44. Choi BH, Ahn IS, Kim YH, et al. Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3-L1 adipocyte. Exp Mol Med 2006;38:599-605
45. Brusq JM, Ancellin N, Grondin P, et al. Inhibition of lipid synthesis through activation of AMP kinase: An additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 2006;47:1281-8
46. Fatehi-Hassanabad Z, Jafarzadeh M, Tarhini A, et al. The antihypertensive and vasodilator effects of aqueous extract from Berberis vulgaris fruit on hypertensive rats. Phytother Res 2005;19:222-5
47. Peychev L. Pharmacological investigation on the cardiovascular effects of berberine vulgaris on tested animals. Pharmacia 2005;52:118-21
48. Chun YT, Yip TT, Lau KL, et al. A biochemical study on hypotensive effects of berberine in rats. Gen Pharmacol 1979;10:177-82
49. Wong KK. Mechanism of the aortic relaxation induced by low concentrations of berberine. Planta Med 1998;64:756-7
50. Ko WH, Yao XQ, Lau CW, et al. Vasorelaxant and antiproliferative effects of berberine. Eur J Pharmacol 2000;399:187-96
51. Kang DG, Sohn EJ, Kwon EK, et al. Effects of berberine on angiotensin-converting enzyme and NO/cGMP system in vessels. Vascul Pharmacol 2002;39:281-6
52. Olmez E, Ilhan M. Evaluation of the alpha-adrenoceptor antagonistic action of berberine in isolated organs. Arzneimittelforschung 1992;42:1095-7
53. Chiou WE, Yen MH, Chen CF. Mechanism of vasodilatory effect of berberine in rat mesenteric artery. Eur J Pharmacol 1991;204:35-40
54. Pan LR, Tang Q, Fu Q, et al. Roles of nitric oxide in protective effect of berberine in ethanol-induced gastric ulcer mice. Acta Pharmacol Sin 2005;26:1334-8
55. Ko WH, Yao XO, Lau CW, et al. Vasorelaxant and antiproliferative effects of berberine. Eur J Pharmacol 2000;399:187-96
56. Liang KW, Yin SC, Ting CT, et al. Berberine inhibits platelet-derived growth factor-induced growth and migration partly through an AMPK-dependent pathway in vascular smooth muscle cells. Eur J Pharmacol 2008;590:343-54
57. Liang KW, Ting CT, Yin SC, et al. Berberine suppresses MEK/ERKdependent Egr-1 signalling pathway and inhibits vascular smooth muscle regrowth after in vitro mechanical injury. Biochem Pharmacol 2006;71:806-17
58. Cho BJ, Im EK, Kwon JH, et al. Berberine inhibits the production of lysophosphatidylcholine-induced reactive oxygen species and the ERK1,2 pathway in smooth muscle cells. Mol Cells 2005;20:429-34
59. Hong Y, Hui SS, Chan BT, et al. Effect of berberine on catecholamine levels in rats with experimental cardiac hypertrophy. Life Sci 2003;72:2499-507
60. Hong Y, Hui SC, Chan TY, et al. Effect of berberine on regression of pressure overload induced cardiac hypertrophy in rats. Am J Chin Med 2002;30:589-99
61. Huang WM, Yan H, Jin JM, et al. Beneficial effects of berberine on hemodynamics during acute ischemic left ventricular failure in dogs. Chin Med J 1992;105:1014-19
62. Wang YX, Zheng YM, Zhou XB. Inhibitory effects of berberine on ATP-sensitive K+ channels in cardiac myocytes. Eur J Pharmacol 1996;316:307-15
63. Tan W, Lu J, Huang M, et al. Anti-cancer natural products isolated from Chinese medicinal herbs. Chin Med 2011;6:27
64. Guo Y, Pope C, Cheng X, et al. Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice. J Ethnopharmacol 2011;138:111-18
65. Tsai PL, Tsai TH. Hepatobiliary excretion of berberine. Drug Metab Dispos 2004;32:405-12
66. Lan T, Shen X, Liu P, et al. Berberine ameliorates renal injury in diabetic C57BL/6 mice: Involvement of suppression of SphK-S1P signaling pathway. Arch Biochem Biophys 2010;502(2):112-20
67. Liu L, Yu YL, Yang JS, et al. Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study. Naunyn Schmiedebergs Arch Pharmacol 2010;381:371-81
68. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008;57:712-17
69. Zhang H, Wei J, Xue R, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 2010;59:285-92
70. Gu Y, Zhang Y, Shi X, et al. Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta 2010;81:766-72
71. Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 2008;93(7):2559-65
72. Affuso F, Ruvolo A, Micillo F, et al. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis 2010;20:656-61
73. Affuso F, Mercurio V, Ruvolo A, et al. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol 2012;4:77-83
74. Cheng F, Wang Y, Li J, et al. Berberine improves endothelial function by reducing endothelial microparticles-mediated oxidative stress in humans. Int J Cardiol 2012;doi: 10.1016/j.ijcard.2012.03.090
75. Cicero A, Derosa G, Maffioli P, et al. Long-term effects of a berberine based nutraceutical on body weight and insulin-sensitivity in nondiabetic hyperlipidaemic patients. J Hypert 2011;29(e-Suppl A):e160
76. Cicero AF, Rovati LC, Setnikar I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. Arzneimittelforschung 2007;57:26-30
77. Kong WJ, Wei J, Zuo ZY, et al. Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism 2008;57:1029-37
78. Xu MG, Wang JM, Chen L, et al. Berberine-induced upregulation of endothelial progenitor cells in related to nitric oxide production in healthy subjects. Cardiology 2008;112:279-86
79. Xu MG, Wang JM, Chen L, et al. Berberine-induced mobilization of circulating endothelial progenitor cells improves human small artery elasticity. J Hum Hypertens 2008;22:389-93
80. Wang JM, Yang Z, Xu MG, et al. Berberine induced decline in circulating CD31(+)/CD42(-) microparticles is associated with improvement of endothelial function in humans. Eur J Pharmacol 2009;614:77-83
81. Marin-Neto JA, Maciel BC, Secches AL, et al. Cardiovascular effects of berberine in patients with severe congestive heart failure. Clin Cardiol 1988;11:253-60
82. Zeng XH, Zeng XJ, Li YY. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2003;92:173-6
83. Lau CW, Yao XQ, Chen ZY, et al. Cardiovascular actions of berberine. Cardiovasc Drug Rev 2001;19:234-44
84. Huang CG, Chu ZL, Wei SJ, et al. Effects of berberine on arachidonic acid metabolism in rabbit platelets and endothelial cells. Thromb Res 2002;106(4-5):223-7
85. Huang CG, Chu ZL, Yang ZM. The progress in pharmacological researches on berberine. Comun Inform Pharm 1991;9:10-12
86. Hoy EW, Akhmedov A, Luscher TF, et al. Berberine a natural lipid-lowering drug, exerts prothrombic effects on vascular cells. J Mol Cell Cardiol 2009;46:234-40
87. Guo Y, Wang QZ, Li FM, et al. Biochemical pathways in the antiatherosclerotic effect of berberine. Chin Med J (Eng) 2008;121:1197-203
88. Pandey MK, Sung B, Kunnumakkara AB, et al. Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappa-Bregulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res 2008;68:5370-9
89. Hwang JM, Wang CJ, Chou FP, et al. Inhibitory effect of berberine on tertbutyl-hydroperoxide-induced oxidative damage in rat liver. Arch Toxicol 2002;76:664-70
90. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol lowering drug working through a unique mechanism distinct from statins. Nat Med 2004;10(12):1344-51
91. Zhao W, Xue R, Zhou ZX, et al. Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis. Biomed Pharmacother 2008;62(10):730-1
92. Cicero AFG, Ertek S. Natural sources of antidyslipidaemic agents: Is there an evidence-based approach for their prescription? Med J Nutr Metab 2008;1(2):85-93